Table 1.
Patient characteristics
| n (%) | |
|---|---|
| Patients (n) | 41 (100%) |
| Age range (years) | |
| 40–49 | 3 (7.3%) |
| 50–59 | 12 (29.3%) |
| 60–69 | 13 (31.7%) |
| 70–79 | 10 (24.4%) |
| 80–89 | 3 (7.3%) |
| FIGO cancer stagea | |
| IAG unspecified | 1 (2.4%) |
| IBG1 | 3 (7.3%) |
| IBG2 | 4 (9.8%) |
| IBG3 | 8 (19.5%) |
| IBG unspecified | 1 (2.4%) |
| ICG1 | 2 (4.9%) |
| ICG2 | 3 (7.3%) |
| ICG3 | 1 (2.4%) |
| ICG unspecified | 2 (4.9%) |
| IIAG1 | 1 (2.4%) |
| IIAG2 | 1 (2.4%) |
| IIAG3 | 1 (2.4%) |
| IIBG1 | 1 (2.4%) |
| IIBG2 | 2 (4.9%) |
| IIBG3 | 2 (4.9%) |
| IIIAG3 | 2 (4.9%) |
| IIIAG unspecified | 1 (2.4%) |
| IIICG2 | 2 (4.9%) |
| IIICG3b | 3 (7.3%) |
| Unspecified (high-grade)c | 1 (2.4%)d |
| Grading | |
| G1 | 7 (17.1%) |
| G2 | 12 (29.3%) |
| G3 | 16 (39%) |
| G unspecified | 6 (14.6%) |
| Time (days) from hysterectomy to first EBTe | |
| Mean ± SD | 96.2 ± 60.1 |
| Median | 80.0 |
| Range | 20–255 |
Notes:
a
Federation International Gynecology and Obstetrics (FIGO) gynecologic cancer staging system;
b
one patient in this group was treated for recurrent endometrial cancer;
c
the “unspecified (high-grade)” cancer was a primary endometrial cancer;
d
due to rounding, numbers do not total exactly 100%;
e
includes only patients with primary endometrial cancer in this study.
Abbreviations: EBT, electronic brachytherapy, SD, standard deviation.